News

The last holdout bears are Democrats, say strategists. Their capitulation could fuel the next leg higher for stocks.
The stock market has seen a historic rally this spring, but not all investors are on board. Ned Davis researchers point the ...
Fourth of July gasoline prices may be the lowest in years. Will gas stay this cheap all summer?
U.S. drivers may pay the lowest Independence Day prices for gasoline at the pump since 2021. But whether cheaper fuel prices ...
This income fund pays more than a bank account while keeping price volatility low
Portfolio manager Laura Mayfield says some individual investors “are focused on the dividend-yield return, but some might be ...
‘There is tension in the house’: I live with my daughter and her lazy boyfriend. She wants me to buy her house.
There is tension in the house. When I say anything, I am immediately wrong — unless my daughter wants something, and then she ...
S&P 500 just saw its first ‘golden cross’ in more than 2 years. Here’s what comes next.
The S&P 500 is kicking off the second half of 2025 in style. For the first time in more than two years, the benchmark index ...
Survey finds investors split nearly 50-50 on expected market reaction to July 9 tariff deadline
A Deutsche Bank survey is asking investors what they're looking for on July 9, when a pause on the so-called reciprocal ...
‘Love is Blind’ hosts Nick and Vanessa Lachey list their SoCal home for $7.4 million just a year after buying it
Nick, 51, and Vanessa, 44, purchased the six-bedroom abode in July 2024, one month before they sold their stunning Honolulu ...
Defense stock surge triggers one of the hottest ETF launches in European history
WisdomTree said its Europe Defence (spelled the British way) UCITS ETF IT:WDEF, launched on March 11, has already surpassed ...
These are the 5 fastest-charging electric cars of 2025
In the time it takes to stretch your legs and order a cup of coffee, these EVs can get enough juice for more than a couple of ...
Organon Will Discontinue Development of Drug to Treat Endometriosis-Related Pain
Organon will discontinue its OG-6219 clinical-development program, after the investigational candidate failed to meet its primary efficacy endpoint in treating endometriosis-related pain.